Alkermes plc

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Alkermes plc
Former names
Antler Science Two PLC
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Headquarters city
Dublin 4
Headquarters country
Ireland
Fiscal year end
December
Ticker symbol
ALKS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001520262
EIN
98-1007018

Board of directors

Follow this board

Chief executives

Richard F. Pops · Director and CEO, Alkermes plc
Dates unknown
Blair Curtis Jackson · President & CEO, Alkermes plc
Dates unknown

Director election results

Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 13 other boards.

Network of Alkermes plc's board connections Amneal Pharmaceuticals Inc. Amneal Pharmaceuticals... Cabot Corporation Cabot Corporation Collegium Pharmaceutical Inc. Collegium Pharmaceutic... Cytokinetics Incorporated Cytokinetics Incorpora... DENTSPLY SIRONA Inc. DENTSPLY SIRONA Inc. EyePoint Inc. EyePoint Inc. ICON plc ICON plc MiMedx Group Inc MiMedx Group Inc Neurocrine Biosciences Inc. Neurocrine Biosciences... Novanta Inc. Novanta Inc. OraSure Technologies Inc. OraSure Technologies I... Prothena Corporation plc Prothena Corporation p... Zai Lab Limited Zai Lab Limited Anne Clem Whitaker Anne Clem Whitaker Brian P. Mckeon Brian P. Mckeon Cato T. Laurencin Cato T. Laurencin Emily Peterson Alva Emily Peterson Alva Frank Anders Wilson Frank Anders Wilson Nancy Lurker Nancy Lurker Nancy Wysenski Nancy Wysenski Richard F. Pops Richard F. Pops Richard Gaynor Richard Gaynor Shane Cooke Shane Cooke Alkermes plc
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$10,479,192
33 sales by 7 insiders
Date Insider Transaction Shares Price Value
Sep 3, 2026 Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) Open-market sale −2,034 $48.01 $97,652
Sep 1, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Option exercise +5,000 $24.59 $122,950
Sep 1, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Open-market sale −9,000 $46.99 $422,874
Aug 17, 2026 Nichols Christian Todd Officer (SVP, Chief Commercial Officer) Open-market sale −6,912 $49.19 $339,967
Aug 17, 2026 Nichols Christian Todd Officer (SVP, Chief Commercial Officer) Open-market sale −664 $49.65 $32,969
Aug 3, 2026 Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) Open-market sale −2,034 $48.58 $98,812
Aug 3, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Option exercise +104 $19.34 $2,011
Aug 3, 2026 Nancy Lynn Snyderman M.D. Director Option exercise +27,948 $46.72 $1,305,731
Aug 3, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Option exercise +4,896 $24.59 $120,393
Aug 3, 2026 Nancy Lynn Snyderman M.D. Director Option exercise +16,524 $46.72 $772,001
Aug 3, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Open-market sale −9,000 $48.58 $437,220
Aug 3, 2026 Nancy Lynn Snyderman M.D. Director Open-market sale −44,472 $50.35 $2,239,076
Jul 6, 2026 Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) Open-market sale −2,034 $54.03 $109,897
Jul 1, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Option exercise +5,000 $19.34 $96,700
Jul 1, 2026 Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) Open-market sale −8,300 $51.46 $427,129

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.